Baidu
map

NEJM:低-中SYNTAX评分的左主干病变患者接受PCI 的3年临床预后不劣于搭桥

2016-12-15 许菁 中国循环杂志

美国哥伦比亚大学 Gregg W. Stone等在新英格兰医学杂志发表研究显示,低-中SYNTAX评分的左主干病变患者接受PCI 的3年临床预后并不劣于搭桥。本组数据显示,PCI组的3年主要终点事件(全因死亡、脑卒中或心肌梗死)发生率为 15.4%,搭桥组为 14.7%,两组无差异。30 天内死亡、 脑卒中或心肌梗死的次要终点事件发生率在PCI组为 4.9%,显著低于搭桥组(7.9%)。3 年次要

美国哥伦比亚大学 Gregg W. Stone等在新英格兰医学杂志发表研究显示,低-中SYNTAX评分的左主干病变患者接受PCI 的3年临床预后并不劣于搭桥。

本组数据显示,PCI组的3年主要终点事件(全因死亡、脑卒中心肌梗死)发生率为 15.4%,搭桥组为 14.7%,两组无差异。

30 天内死亡、 脑卒中或心肌梗死的次要终点事件发生率在PCI组为 4.9%,显著低于搭桥组(7.9%)。

3 年次要终点事件(死亡、 脑卒中、 心肌梗死或心肌缺血所致血运重建)发生率在 PCI组为 23.1%,搭桥组为19.1%,两组无差异。

研究纳入 1905例左主干病变患者,948 例患者接受PCI,957 例接受搭桥。

原始出处:


Gregg W. Stone, Joseph F. Sabik, Patrick W. Serruys, et al. Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. N Engl J Med, 2016
拓展阅读:心梗相关的拓展阅读:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1663896, encodeId=a332166389692, content=<a href='/topic/show?id=03a35691e2e' target=_blank style='color:#2F92EE;'>#搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56917, encryptionId=03a35691e2e, topicName=搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=557f25711234, createdName=12498b3em16(暂无昵称), createdTime=Wed Oct 11 20:05:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958271, encodeId=15eb19582e13e, content=<a href='/topic/show?id=d0261699334' target=_blank style='color:#2F92EE;'>#SYNTAX评分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16993, encryptionId=d0261699334, topicName=SYNTAX评分)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Wed Mar 29 00:05:00 CST 2017, time=2017-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718528, encodeId=84a51e185282c, content=<a href='/topic/show?id=35534e966a0' target=_blank style='color:#2F92EE;'>#左主干#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47966, encryptionId=35534e966a0, topicName=左主干)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5fa32580320, createdName=cathymary, createdTime=Mon Nov 06 16:05:00 CST 2017, time=2017-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163556, encodeId=1990163556c1, content=期待更长时间随访结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Dec 17 15:49:52 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534706, encodeId=83ab1534e06a7, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Sat Dec 17 02:05:00 CST 2016, time=2016-12-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1663896, encodeId=a332166389692, content=<a href='/topic/show?id=03a35691e2e' target=_blank style='color:#2F92EE;'>#搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56917, encryptionId=03a35691e2e, topicName=搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=557f25711234, createdName=12498b3em16(暂无昵称), createdTime=Wed Oct 11 20:05:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958271, encodeId=15eb19582e13e, content=<a href='/topic/show?id=d0261699334' target=_blank style='color:#2F92EE;'>#SYNTAX评分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16993, encryptionId=d0261699334, topicName=SYNTAX评分)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Wed Mar 29 00:05:00 CST 2017, time=2017-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718528, encodeId=84a51e185282c, content=<a href='/topic/show?id=35534e966a0' target=_blank style='color:#2F92EE;'>#左主干#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47966, encryptionId=35534e966a0, topicName=左主干)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5fa32580320, createdName=cathymary, createdTime=Mon Nov 06 16:05:00 CST 2017, time=2017-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163556, encodeId=1990163556c1, content=期待更长时间随访结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Dec 17 15:49:52 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534706, encodeId=83ab1534e06a7, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Sat Dec 17 02:05:00 CST 2016, time=2016-12-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1663896, encodeId=a332166389692, content=<a href='/topic/show?id=03a35691e2e' target=_blank style='color:#2F92EE;'>#搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56917, encryptionId=03a35691e2e, topicName=搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=557f25711234, createdName=12498b3em16(暂无昵称), createdTime=Wed Oct 11 20:05:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958271, encodeId=15eb19582e13e, content=<a href='/topic/show?id=d0261699334' target=_blank style='color:#2F92EE;'>#SYNTAX评分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16993, encryptionId=d0261699334, topicName=SYNTAX评分)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Wed Mar 29 00:05:00 CST 2017, time=2017-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718528, encodeId=84a51e185282c, content=<a href='/topic/show?id=35534e966a0' target=_blank style='color:#2F92EE;'>#左主干#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47966, encryptionId=35534e966a0, topicName=左主干)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5fa32580320, createdName=cathymary, createdTime=Mon Nov 06 16:05:00 CST 2017, time=2017-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163556, encodeId=1990163556c1, content=期待更长时间随访结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Dec 17 15:49:52 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534706, encodeId=83ab1534e06a7, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Sat Dec 17 02:05:00 CST 2016, time=2016-12-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1663896, encodeId=a332166389692, content=<a href='/topic/show?id=03a35691e2e' target=_blank style='color:#2F92EE;'>#搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56917, encryptionId=03a35691e2e, topicName=搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=557f25711234, createdName=12498b3em16(暂无昵称), createdTime=Wed Oct 11 20:05:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958271, encodeId=15eb19582e13e, content=<a href='/topic/show?id=d0261699334' target=_blank style='color:#2F92EE;'>#SYNTAX评分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16993, encryptionId=d0261699334, topicName=SYNTAX评分)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Wed Mar 29 00:05:00 CST 2017, time=2017-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718528, encodeId=84a51e185282c, content=<a href='/topic/show?id=35534e966a0' target=_blank style='color:#2F92EE;'>#左主干#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47966, encryptionId=35534e966a0, topicName=左主干)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5fa32580320, createdName=cathymary, createdTime=Mon Nov 06 16:05:00 CST 2017, time=2017-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163556, encodeId=1990163556c1, content=期待更长时间随访结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Dec 17 15:49:52 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534706, encodeId=83ab1534e06a7, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Sat Dec 17 02:05:00 CST 2016, time=2016-12-17, status=1, ipAttribution=)]
    2016-12-17 owlhealth

    期待更长时间随访结果

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1663896, encodeId=a332166389692, content=<a href='/topic/show?id=03a35691e2e' target=_blank style='color:#2F92EE;'>#搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56917, encryptionId=03a35691e2e, topicName=搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=557f25711234, createdName=12498b3em16(暂无昵称), createdTime=Wed Oct 11 20:05:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958271, encodeId=15eb19582e13e, content=<a href='/topic/show?id=d0261699334' target=_blank style='color:#2F92EE;'>#SYNTAX评分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16993, encryptionId=d0261699334, topicName=SYNTAX评分)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Wed Mar 29 00:05:00 CST 2017, time=2017-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718528, encodeId=84a51e185282c, content=<a href='/topic/show?id=35534e966a0' target=_blank style='color:#2F92EE;'>#左主干#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47966, encryptionId=35534e966a0, topicName=左主干)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5fa32580320, createdName=cathymary, createdTime=Mon Nov 06 16:05:00 CST 2017, time=2017-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163556, encodeId=1990163556c1, content=期待更长时间随访结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Dec 17 15:49:52 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534706, encodeId=83ab1534e06a7, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Sat Dec 17 02:05:00 CST 2016, time=2016-12-17, status=1, ipAttribution=)]

相关资讯

Plos Med:卒中和短暂性脑缺血发作一级预防药物治疗需要加大处方力度!

超过一半的人适合降脂、抗凝或抗高血压药物治疗,但在发生第一次卒中和短暂性脑缺血发作之前在处方中都没有写明需要服用这些药物。研究人员估计,如果通过将这些药物最佳时机写入处方,在英国每年约有12000次卒中事件可能会被预防。提高降脂、抗凝和抗高血压药物写入处方的比例是降低卒中和短暂性脑缺血发作发病率和负担的重要措施。

中国证据:T2DM患者BMI与死亡率呈U型相关

导语:2016年10月,Journal of Diabetes and its Complications发表一项前瞻性队列研究,通过收集分析开滦研究的数据,探究中国2型糖尿病(T2DM)患者体重指数(BMI)对全因死亡率的影响。肥胖是糖尿病的危险因素之一,体重增长会增加发生糖尿病的可能性,然而,对于超重或肥胖的终末期肾病(ESRD)、高血压、心衰患者,死亡风险反而降低,这就是著名的“肥胖悖论”。

Neurology:脑卒中后骨折的风险增加

卒中与轻度创伤性骨折的风险增加有关。伴有骨折额外危险因素的卒中患者可能会受益于有针对性地进行低骨密度个体筛选和开始骨折预防性的治疗。

2016 AHA/ASA科学声明:卒中后抑郁

2016年12月,美国心脏协会(AHA)联合美国卒中协会(ASA)共同发布了卒中后抑郁的共识声明,卒中后抑郁比较常见,大约影响着1/3的卒中幸存者,卒中后抑郁可发生在卒中后任何时间。本文为来自AHA和ASA的第一版卒中后抑郁共识声明,全面探讨了卒中后抑郁的流行病学,病理生理学,结局,管理以及预防等。下载地址:下载   (需要扣积分2分, 梅斯医学APP免积分下载) 

Lancet:全球房颤患者诊疗大比拼:中国卒中发生率竟与非洲比肩,原来是这两件事儿未做好

Lancet杂志近期公布了RELY房颤注册研究全球47个国家的急诊房颤注册结果。该研究共登记约1.5例房颤患者,并随访了1年,其中4%的患者发生了卒中。中国房颤患者1年卒中发生率7%,仅次于非洲(8%)。印度最低(1%),北美3%。 中国有服用抗凝药物指证的房颤患者中,有70%未应用抗凝药物。在47个国家中最差。但作者也表示,除抗凝药物应用不足之外,中国和非洲的卒中发生率高,也与高血压控

Baidu
map
Baidu
map
Baidu
map